Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa.
Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa.
复制标题
DOI：
10.1080/21655979.2021.1958600
复制
发表时间：
2021-12
期刊：
影响因子：
4.9
通讯作者：
Kuang H
中科院分区：
文献类型：
--
作者：
Li D;Yang Y;Yin X;Liu Y;Xu H;Ni Y;Hang P;Niu S;Zhang H;Ding W;Kuang H
溃疡性结肠炎（UC）的全球发病率持续增加，但临床治愈率仍然较低。肠粘膜溃疡呈节段性分布，严重程度不等。肠道细菌与肠道免疫、代谢密切相关；然而，肠道微生物组特征与 UC 发生之间的关系以及葡萄糖代谢的贡献尚不清楚。本研究使用 UC 患者和健康对照受试者的粘膜活检对此进行了调查。我们进行了高通量 16S rRNA 基因测序，以估计微生物群组成和丰度以及它们与病变严重程度等临床指标的关联。结果显示，UC患者肠道菌群的多样性和丰度显着低于健康受试者；然而，这些与溃疡的严重程度无关。血清胰高血糖素样肽 2 (GLP-2) 水平与 UC 中微生物群多样性和丰度降低相关。这些结果表明，特定微生物群的定植并不是 UC 病理状态的主要决定因素。此外，增加肠粘膜中 GLP-2 水平的治疗策略可能对治疗 UC 有效。
The global incidence of ulcerative colitis (UC) continues to increase while it’s clinical cure rate remains low. Intestinal mucosal ulcers have segmental distribution and variable severity. Intestinal bacteria are closely related to intestinal immunity and metabolism; however, the relationship between intestinal microbiome profile and the occurrence of UC, as well as the contribution of glucose metabolism, are not well understood. This was investigated in the present study using mucosal biopsies from patients with UC and healthy control subjects. We performed high throughput 16S rRNA gene sequencing to estimate microbiota composition and abundance as well as their association with clinical indices such as lesion severity. The results showed that the diversity and abundance of intestinal microbiota were significantly lower in patients with UC than in healthy subjects; however, these were unrelated to ulcer severity. Serum glucagon-like peptide 2 (GLP-2) level was associated with reduced microbiota diversity and abundance in UC. These results indicate that colonization by specific microbiota is not the main determinant of pathologic status in UC. Additionally, therapeutic strategies that increase GLP-2 levels in intestinal mucosa may be effective in the treatment of UC.
登录
查看更多内容
具有高免疫调节能力的转基因免疫生物的应用，用于治疗炎症性肠病。
影响因子：
7.3
作者：
Shigemori S;Shimosato T
通讯作者：
Shimosato T
影响因子：
64.8
作者：
Arumugam, Manimozhiyan;Raes, Jeroen;Pelletier, Eric;Le Paslier, Denis;Yamada, Takuji;Mende, Daniel R.;Fernandes, Gabriel R.;Tap, Julien;Bruls, Thomas;Batto, Jean-Michel;Bertalan, Marcelo;Borruel, Natalia;Casellas, Francesc;Fernandez, Leyden;Gautier, Laurent;Hansen, Torben;Hattori, Masahira;Hayashi, Tetsuya;Kleerebezem, Michiel;Kurokawa, Ken;Leclerc, Marion;Levenez, Florence;Manichanh, Chaysavanh;Nielsen, H. Bjorn;Nielsen, Trine;Pons, Nicolas;Poulain, Julie;Qin, Junjie;Sicheritz-Ponten, Thomas;Tims, Sebastian;Torrents, David;Ugarte, Edgardo;Zoetendal, Erwin G.;Wang, Jun;Guarner, Francisco;Pedersen, Oluf;de Vos, Willem M.;Brunak, Soren;Dore, Joel;Weissenbach, Jean;Ehrlich, S. Dusko;Bork, Peer
通讯作者：
Bork, Peer
影响因子：
--
作者：
Fang H;Fu L;Wang J
通讯作者：
Wang J
影响因子：
4.3
作者：
Babickova, Janka;Gardlik, Roman
通讯作者：
Gardlik, Roman
影响因子：
29.4
作者：
Swidsinski, A;Ladhoff, A;Lochs, H
通讯作者：
Lochs, H